Nuo Therapeutics, Inc.

Nuo Therapeutics, Inc.

OOTC:AURX
1.09
USD
+0.02
(+1.87%)
-0.04EPS
48.89MMarket Cap
Mar 03Next Earn

Total Valuation

USD

As of June 30, 2026, Nuo Therapeutics, Inc. carries a market capitalization of 48.89M, placing it among publicly traded companies globally. Its enterprise value stands at 50.25M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap48.89M
Enterprise Value50.25M

Important Dates

Nuo Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 3, 2027.

Earnings Date3/3/2027

Share Statistics

As of June 30, 2026, Nuo Therapeutics, Inc. has 48.41M shares outstanding.

Shares Outstanding48.41M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 9.94, and the price-to-book ratio stands at -31.85.

PS Ratio9.94
PB Ratio-31.85
P/TBV Ratio-31.85
P/FCF Ratio-32.71
P/OCF Ratio-40.98

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 10.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 50.25M versus a market cap of 48.89M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales10.32

Financial Position

As of June 30, 2026, Nuo Therapeutics, Inc. maintains a current ratio of 1.28, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities.

Current Ratio1.28
Quick Ratio1.04
Debt / Equity-117.91
Debt / EBITDA-1.08

Financial Efficiency

USD

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -112.60, reflecting losses generated across the asset base. The company generates approximately 499,295.69 in revenue per employee across its workforce of 9.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.78 indicates how many times Nuo Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-112.60
Revenue Per Employee499,295.69
Employee Count9.75
Inventory Turnover8.78

Stock Price Statistics

USD

As of the close on November 11, 2026, Nuo Therapeutics, Inc.'s stock has declined approximately 53.81% over the past 52 weeks. The 50-day moving average sits at 1.16, while the 200-day moving average is 1.56.

52-Week Price Change-53.81%
50-Day Moving Average1.16
200-Day Moving Average1.56

Income Statement

USD

Over the twelve months ended June 30, 2026, Nuo Therapeutics, Inc. generated 4.87M in revenue and converted that into -2.12M in net income, yielding earnings per share of -0.04. EBITDA reached -1.67M, while operating income came in at -1.84M.

Revenue4.87M
Gross Profit3.25M
Operating Income-1.84M
Pretax Income-2.12M
Net Income-2.12M
EBITDA-1.67M
EBIT-1.84M
Earnings Per Share (EPS)-0.04

Balance Sheet

USD

As of June 30, 2026, Nuo Therapeutics, Inc. holds 449,325.00 in cash and equivalents against 1.81M in total debt, resulting in a net debt position of 1.30M. Total book value stands at -1.54M, with working capital of 439,434.00 providing operational flexibility.

Cash & Cash Equivalents449,325.00
Total Debt1.81M
Net Debt1.30M
Equity (Book Value)-1.54M
Book Value Per Share-0.03
Working Capital439,434.00

Cash Flow

USD

Nuo Therapeutics, Inc. produced -1.18M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -298,746.00 in capital expenditures, free cash flow totaled -1.48M - equivalent to -0.03 per share.

Operating Cash Flow-1.18M
Capital Expenditures-298,746.00
Free Cash Flow-1.48M
FCF Per Share-0.03

Margins

Over the twelve months ended June 30, 2026, Nuo Therapeutics, Inc. posted a gross margin of 66.74, reflecting its pricing power and cost economics. The operating margin of -37.89 and net profit margin of -43.64 provide insight into operational efficiency.

Gross Margin66.74
Operating Margin-37.89
Pretax Margin-43.64
Profit Margin-43.64
EBITDA Margin-34.40

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of -2.37 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -3.06: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.43, meaning Nuo Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Payout Ratio-2.37
Shareholder Yield-3.43
FCF Yield-3.06

Scores

As of June 30, 2026, Nuo Therapeutics, Inc. has an Altman Z-Score of -12.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-12.23